French Guiana, France

Confirmed cases per 1000 population
- Insufficient data
- 0
- 0–0.1
- 0.1–1.0
- 1.0–10
- 10–50
- 50–100
- ≥100

Proportion of cases due to *P. falciparum*
- Insufficient data
- no cases
- Very low PP
- 0–20
- 20–40
- 40–60
- 60–80
- 80–100

I. Epidemiological profile

Population	2013	%
High transmission (> 1 case per 1000 population)	213 000	86
Low transmission (0–1 cases per 1000 population)	36 100	14
Malaria-free (0 cases)	0	0
Total	249 100	

Parasites and vectors	
Major plasmodium species:	*P. falciparum* (31%), *P. vivax* (68%)
Major anopheles species:	*An. darlingi*
Programme phase:	Control
Reported confirmed cases:	875
Reported deaths:	3

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2012
	ITNs/LLINs distributed to all age groups	Yes	2012
IRS	IRS is recommended	Yes	–
	DDT is authorized for IRS	No	–
Larval control	Use of larval control recommended	Yes	–
IPT	IPT used to prevent malaria during pregnancy	N/A	–
Diagnosis	Patients of all ages should receive diagnostic test	Yes	–
	Malaria diagnosis is free of charge in the public sector	Yes	–
Treatment	ACT is free for all ages in public sector	–	–
	Artemisinin-based monotherapies withdrawn	–	–
	Single dose of primaquine is used as gametocidal medicine for *P. falciparum*	Yes	–
	Primaquine is used for radical treatment of *P. vivax*	Yes	–
	G6PD test is a requirement before treatment with primaquine	–	–
	Directly observed treatment with primaquine is undertaken	–	–
	System for monitoring of adverse reactions to antimalarials exists	–	–

Intervention	Policies/strategies	Yes/No	Year adopted
Surveillance	ACD for case investigation (reactive)	–	–
	ACD of febrile cases at community level (pro-active)	–	–
	Mass screening is undertaken	–	–
	Uncomplicated *P. falciparum* cases routinely admitted	–	–
	Uncomplicated *P. vivax* cases routinely admitted	–	–

Antimalaria treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	–	–
First-line treatment of *P. falciparum*	AL; AT+PG	–
Treatment failure of *P. falciparum*	–	–
Treatment of severe malaria	AS; QN+D	–
Treatment of *P. vivax*	CQ+PQ	–
Dosage of primaquine for radical treatment of *P. vivax*		–
Type of RDT used		*P.f + P.v, P.o, P.m* (Combo)

Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
–	–	–	–	–	–	–	–

III. Financing

Sources of financing



Financing by intervention in 2013

No data reported for 2013

IV. Coverage

ITN and IRS coverage



Cases tested and treated in public sector



Cases tracked



Test positivity



V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths



Impact: Achieved >75% decrease in case incidence in 2013